Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Vazyme Biotech CoSHSE:688105 +0.95%74 5-Year Yield-on-Cost % is 2.43 as of Sep. 03, 2026, which is 216% above its 10-year median of 0.77. GuruFocus rates SHSE:688105 with a GF Score™ of 74/100 and a GF Value™ of ¥21.20 (Fairly Valued). The stock has 2 warning signs investors should review. Among 149 Biotechnology companies, Nanjing Vazyme Biotech Co ranks better than 59.06% on this metric.
The historical rank and industry rank for Nanjing Vazyme Biotech Co's 5-Year Yield-on-Cost % or its related term are showing as below:
SHSE:688105'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.36 Med: 0.77 Max: 6.25
Current: 2.43
During the past 9 years, Nanjing Vazyme Biotech Co's highest Yield on Cost was 6.25. The lowest was 0.36. And the median was 0.77.
SHSE:688105's 5-Year Yield-on-Cost % is ranked better than 59.06% of 149
companies
in the Biotechnology industry
Industry Median: 1.58
vs SHSE:688105: 2.43
Nanjing Vazyme Biotech Co (SHSE:688105) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Nanjing Vazyme Biotech Co 5-Year Yield-on-Cost % Related Terms
SHSE:688105 vs VRTX, REGN, MRNA: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Nanjing Vazyme Biotech Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Vazyme Biotech Co 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Vazyme Biotech Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Nanjing Vazyme Biotech Co's 5-Year Yield-on-Cost % falls into.
Nanjing Vazyme Biotech Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Nanjing Vazyme Biotech Co (SHSE:688105) has a 5-Year Yield-on-Cost % of 2.43 as of Sep. 03, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Nanjing Vazyme Biotech Co and its competitors. This is 216% above median its historical median of 0.77. Over the past decade, Nanjing Vazyme Biotech Co's 5-Year Yield-on-Cost % has ranged from 0.36 to 6.25. According to the industry distribution chart, Nanjing Vazyme Biotech Co ranks #61 out of 149 companies in the Biotechnology industry, placing it in the top 40.9%.
Is Nanjing Vazyme Biotech Co's 5-Year Yield-on-Cost % too high?
Nanjing Vazyme Biotech Co's current 5-Year Yield-on-Cost % of 2.43 is 216% above median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 6.25. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.58. Nanjing Vazyme Biotech Co's value of 2.43 is 53.8% above this industry median. Based on the distribution chart, Nanjing Vazyme Biotech Co ranks #61 out of 149 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nanjing Vazyme Biotech Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Vazyme Biotech Co's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Vazyme Biotech Co ranks #61 out of 149 companies for 5-Year Yield-on-Cost %. This puts Nanjing Vazyme Biotech Co in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 1.58. Nanjing Vazyme Biotech Co's value of 2.43 is 53.8% above this benchmark. Historically, Nanjing Vazyme Biotech Co's own 5-Year Yield-on-Cost % has ranged from 0.36 to 6.25 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 1.58, Nanjing Vazyme Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.58, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Vazyme Biotech Co's current 5-Year Yield-on-Cost % of 2.43 is 53.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Nanjing Vazyme Biotech Co and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Vazyme Biotech Co's current 5-Year Yield-on-Cost % is 2.43, which is 216% above median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Vazyme Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co (SHSE:688105) is currently considered Fairly Valued. The stock's GF Value™ is ¥21.20, compared to a current price of ¥20.25 — trading 4.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.43, which is 216% above median its 10-year median of 0.77 and 53.8% above the Biotechnology industry median of 1.58. Nanjing Vazyme Biotech Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Nanjing Vazyme Biotech Co (SHSE:688105), the current 5-Year Yield-on-Cost % is 2.43 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Vazyme Biotech Co (SHSE:688105) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co stock appears to be undervalued.
The current stock price of ¥20.25 is trading 4.5% below its estimated GF Value™ of ¥21.20.
GuruFocus considers Nanjing Vazyme Biotech Co to be Fairly Valued.
Key valuation signals for SHSE:688105:
5-Year Yield-on-Cost %: 2.43 (216% above median its 10-year median of 0.77)
GF Value™: ¥21.20 vs. price of ¥20.25 (4.5% below fair value)
Industry Position: 53.8% above the Biotechnology median (#61 of 149)
No single metric tells the full story. See the SHSE:688105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressKechuang Road, Floor 1-6, East Section, Building C1-2, Hongfeng Science and Technology Park, Jiangsu, Economic and Technological Development Zone, Nanjing, CHN, 210000
Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.
74GF Score
Get the complete analysis for SHSE:688105
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688105 has been successfully added to your 
